Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron Corporation (NASDAQ:GERN) from $4 to $3 and maintained a Buy rating on the stock. This update comes before the company’s fourth-quarter results, which the company plans to report on February 25.

In other news, on January 12, Geron Corporation (NASDAQ:GERN) shared its financial guidance for 2026. The company expects RYTELO net product revenue to be between $220 million and $240 million. Total operating expenses are projected to range from $230 million to $240 million. Geron Corporation (NASDAQ:GERN) said its 2026 outlook reflects expected revenue growth along with a year-over-year reduction in operating expenses, which it believes supports the strength of its balance sheet.

For 2026, Geron Corporation (NASDAQ:GERN) said its main priorities include growing RYTELO commercially in the US, exploring opportunities to expand RYTELO into lower-risk myelodysplastic syndromes (LR-MDS) markets outside the US, and advancing its Phase 3 IMpactMF trial.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 AI Stocks That Are Skyrocketing and 12 Best Oil and Gas Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.